An	0	2	O
evaluation	3	13	O
of	14	16	O
low	17	20	B-Drug_or_compound
molecular	21	30	I-Drug_or_compound
weight	31	37	I-Drug_or_compound
heparin	38	45	I-Drug_or_compound
and	46	49	O
hyperbaric	50	60	B-Drug_or_compound
oxygen	61	67	I-Drug_or_compound
treatment	68	77	O
in	78	80	O
the	81	84	O
prevention	85	95	O
of	96	98	O
intra	99	104	O
-	104	105	O
abdominal	105	114	O
adhesions	115	124	O
and	125	128	O
wound	129	134	O
healing	135	142	O
.	142	143	O

BACKGROUND	145	155	O
:	155	156	O
Abdominal	157	166	O
surgery	167	174	O
can	175	178	O
lead	179	183	O
to	184	186	O
intra	187	192	O
-	192	193	O
abdominal	193	202	O
adhesions	203	212	O
with	213	217	O
significant	218	229	O
morbidity	230	239	O
and	240	243	O
mortality	244	253	O
.	253	254	O

To	255	257	O
prevent	258	265	O
adhesions	266	275	O
,	275	276	O
an	277	279	O
experimental	280	292	O
study	293	298	O
was	299	302	O
planned	303	310	O
to	311	313	O
designate	314	323	O
the	324	327	O
effects	328	335	O
of	336	338	O
low	339	342	B-Drug_or_compound
molecular	343	352	I-Drug_or_compound
weight	353	359	I-Drug_or_compound
(	360	361	I-Drug_or_compound
LMW	361	364	I-Drug_or_compound
)	364	365	I-Drug_or_compound
heparins	366	374	I-Drug_or_compound
and	375	378	O
hyperbaric	379	389	B-Drug_or_compound
oxygen	390	396	I-Drug_or_compound
(	397	398	O
HBO	398	401	B-Drug_or_compound
)	401	402	O
therapy	403	410	O
both	411	415	O
on	416	418	O
the	419	422	O
formation	423	432	O
of	433	435	O
adhesions	436	445	O
and	446	449	O
wound	450	455	O
healing	456	463	O
.	463	464	O

METHODS	465	472	O
:	472	473	O
Thirty	474	480	O
-	480	481	O
eight	481	486	O
Wistar	487	493	B-Organism
albino	494	500	I-Organism
rats	501	505	I-Organism
underwent	506	515	O
laparotomy	516	526	O
to	527	529	O
cause	530	535	O
intra	536	541	O
-	541	542	O
abdominal	542	551	O
adhesions	552	561	O
by	562	564	O
mechanical	565	575	O
abrasion	576	584	O
of	585	587	O
the	588	591	O
cecum	592	597	B-Multi-tissue_structure
and	598	601	O
ethanol	602	609	B-Drug_or_compound
application	610	621	O
.	621	622	O

The	623	626	O
rats	627	631	B-Organism
were	632	636	O
divided	637	644	O
into	645	649	O
4	650	651	O
groups	652	658	O
.	658	659	O

In	660	662	O
the	663	666	O
control	667	674	O
group	675	680	O
(	681	682	O
group	682	687	O
1	688	689	O
)	689	690	O
no	691	693	O
further	694	701	O
management	702	712	O
was	713	716	O
undertaken	717	727	O
.	727	728	O

Group	729	734	O
2	735	736	O
was	737	740	O
treated	741	748	O
by	749	751	O
Enoxaparine	752	763	B-Drug_or_compound
Na	764	766	I-Drug_or_compound
,	766	767	O
group	768	773	O
3	774	775	O
received	776	784	O
HBO	785	788	B-Drug_or_compound
therapy	789	796	O
,	796	797	O
and	798	801	O
group	802	807	O
4	808	809	O
was	810	813	O
given	814	819	O
both	820	824	O
enoxaparine	825	836	B-Drug_or_compound
Na	837	839	I-Drug_or_compound
and	840	843	O
HBO	844	847	B-Drug_or_compound
treatment	848	857	O
.	857	858	O

RESULTS	859	866	O
:	866	867	O
There	868	873	O
was	874	877	O
a	878	879	O
statistically	880	893	O
significant	894	905	O
difference	906	916	O
between	917	924	O
the	925	928	O
control	929	936	O
and	937	940	O
enoxaparine	941	952	B-Drug_or_compound
Na	953	955	I-Drug_or_compound
groups	956	962	O
regarding	963	972	O
adhesions	973	982	O
.	982	983	O

Statistically	984	997	O
significant	998	1009	O
differences	1010	1021	O
were	1022	1026	O
observed	1027	1035	O
between	1036	1043	O
groups	1044	1050	O
1	1051	1052	O
and	1053	1056	O
4	1057	1058	O
and	1059	1062	O
between	1063	1070	O
groups	1071	1077	O
1	1078	1079	O
and	1080	1083	O
3	1084	1085	O
regarding	1086	1095	O
the	1096	1099	O
hydroxyproline	1100	1114	O
content	1115	1122	O
of	1123	1125	O
the	1126	1129	O
abdominal	1130	1139	O
wounds	1140	1146	O
.	1146	1147	O

In	1148	1150	O
the	1151	1154	O
pathologic	1155	1165	O
analysis	1166	1174	O
of	1175	1177	O
the	1178	1181	O
abdominal	1182	1191	O
wounds	1192	1198	O
,	1198	1199	O
there	1200	1205	O
was	1206	1209	O
no	1210	1212	O
statistically	1213	1226	O
significant	1227	1238	O
difference	1239	1249	O
between	1250	1257	O
any	1258	1261	O
of	1262	1264	O
the	1265	1268	O
groups	1269	1275	O
,	1275	1276	O
including	1277	1286	O
the	1287	1290	O
control	1291	1298	O
group	1299	1304	O
,	1304	1305	O
regarding	1306	1315	O
inflammation	1316	1328	O
.	1328	1329	O

Statistically	1330	1343	O
significant	1344	1355	O
differences	1356	1367	O
were	1368	1372	O
observed	1373	1381	O
regarding	1382	1391	O
angiogenesis	1392	1404	O
between	1405	1412	O
the	1413	1416	O
control	1417	1424	O
group	1425	1430	O
and	1431	1434	O
groups	1435	1441	O
3	1442	1443	O
and	1444	1447	O
4	1448	1449	O
.	1449	1450	O

There	1451	1456	O
was	1457	1460	O
also	1461	1465	O
a	1466	1467	O
statistically	1468	1481	O
significant	1482	1493	O
difference	1494	1504	O
regarding	1505	1514	O
fibrosis	1515	1523	O
between	1524	1531	O
groups	1532	1538	O
1	1539	1540	O
and	1541	1544	O
4	1545	1546	O
.	1546	1547	O

CONCLUSIONS	1548	1559	O
:	1559	1560	O
Enoxaparine	1561	1572	B-Drug_or_compound
Na	1573	1575	I-Drug_or_compound
decreased	1576	1585	O
intra	1586	1591	O
-	1591	1592	O
abdominal	1592	1601	O
adhesions	1602	1611	O
,	1611	1612	O
and	1613	1616	O
HBO	1617	1620	B-Drug_or_compound
therapy	1621	1628	O
had	1629	1632	O
no	1633	1635	O
beneficial	1636	1646	O
effect	1647	1653	O
on	1654	1656	O
adhesions	1657	1666	O
.	1666	1667	O

Enoxaparine	1668	1679	B-Drug_or_compound
Na	1680	1682	I-Drug_or_compound
had	1683	1686	O
no	1687	1689	O
harmful	1690	1697	O
effects	1698	1705	O
on	1706	1708	O
wound	1709	1714	O
healing	1715	1722	O
,	1722	1723	O
and	1724	1727	O
HBO	1728	1731	B-Drug_or_compound
therapy	1732	1739	O
increased	1740	1749	O
the	1750	1753	O
process	1754	1761	O
of	1762	1764	O
wound	1765	1770	O
healing	1771	1778	O
.	1778	1779	O

